Tourmaline Oil Corp. is shifting focus to unlock more liquids potential from its high-quality acreage. Click here to read why ...
Investor's Business Daily on MSN
Why Novartis' $1.4 Billion Takeover Of Tourmaline Bio Just 'Makes Sense'
Tourmaline Bio shares skyrocketed Tuesday after Novartis agreed to buy the cardiovascular-focused biotech company for $1.4 billion.
The market expects Tourmaline Oil Corp. (TRMLF) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2025. This widely-known consensus ...
With free cash flow guidance of $2.6B, Tourmaline intends to return 50-90% of free cash flow to shareholders in 2023. Investors can anticipate a steadily growing base dividend and special dividends ...
Down more than 20% from all-time highs, Tourmaline Oil is a blue-chip TSX stock that is positioned to deliver outsized gains ...
Tourmaline Oil Corp. closed 11.0% short of its 52-week high of C$70.83, which the company reached on February 21st.
Tourmaline Bio, Inc. has announced the appointment of Dr. Paul M. Ridker to its Cardiovascular Scientific Advisory Board. Dr. Ridker, a prominent figure in cardiovascular research from Harvard Medical ...
The deal will boost the Swiss pharmaceutical company’s cardiovascular drug pipeline.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback